HLA-E expression in diffuse glioma: relationship with clinicopathological features and patient survival

• Main Authors: Zhifeng Wu, Jingshan Liang, Zheng Wang, Aimin Li, Xing Fan, Tao Jiang
• Format: Article
• Language: English
• Published: BMC 2020-02-01
• Series: BMC Neurology
• Subjects: Diffuse glioma; HLA-E; Clinical outcome; Prognostic biomarker
• Online Access: http://link.springer.com/article/10.1186/s12883-020-01640-4

Abstract Background Human leukocyte antigen-E (HLA-E) has been extensively investigated in various human cancers including glioma. However, the clinical significance of HLA-E expression in glioma patients has not been elucidated. The current study aimed to investigate the association of HLA-E expression with clinicopathological features and survival in patients with diffuse glioma. Methods A total of 261 glioma patients were enrolled, subsequently, mRNA microarray analysis was conducted to identify the relationship of HLA-E with clinicopathological features and patient survival. Results HLA-E was significantly overexpressed in high-grade gliomas compared to low-grade gliomas (LGGs). Moreover, HLA-E expression was significantly higher in diffuse astrocytomas than oligodendrogliomas (p = 0.032, t-test). Kaplan-Meier analysis showed that progression-free survival (PFS) and overall survival (OS) were significantly better in LGG patients with low HLA-E expression (p = 0.018 for PFS and p = 0.020 for OS, Log-rank test). Furthermore, HLA-E expression was identified to be an independent prognostic factor by Cox analysis (p = 0.020 for PFS and p = 0.024 for OS). Conclusions This is the first study which identified the clinical significance of HLA-E in diffuse glioma. HLA-E expression was correlated with more aggressive tumor grade and histological type and was identified as an independent prognostic biomarker in LGG patients.